CAT
Caterpillar Inc.
CAT's fundamentals are strong, but it looks expensive: trading at 24x earnings, above its usual 18x. Analysts expect strong earnings growth, though they disagree widely on how much.
PSHG
Performance Shipping Inc.
There isn't enough reported data to score PSHG yet.
CAT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
CAT's revenue, profitability, cash flow and balance sheet are all currently healthy.
PSHG Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Stable | |
| Unavailable | |
| Strong |
PSHG's balance sheet is currently strong, and its profitability is stable. There isn't enough data to rate its revenue and cash flow.
CAT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 15x | $380 | -37% |
| Fair | 18x | $461 | -24% |
| Forward | 20x | $605 | — |
| Current | 24x | $605 | — |
| Expensive | 33x | $840 | +39% |
Historical ranges are pointers, not guarantees.
CAT has the edge over PSHG in the historical PE scenario, which offers more potential upside but is not a forecast.
PSHG PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 1.1x | $0.96 | -52% |
| Fair | 1.2x | $1.12 | -45% |
| Expensive | 1.4x | $1.30 | -36% |
| Current | 2.2x | $2.02 | — |
| Forward | 3.3x | $2.02 | — |
Historical ranges are pointers, not guarantees.
PSHG's PE is 2.2x, but its earnings don't support one, so it isn't a reliable read right now.
CAT Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Moderate | |
| Low |
CAT has the edge over PSHG on the outlook, with more favorable valuation and earnings expectations.
PSHG Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong decline | |
| Stable | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect PSHG's earnings and profitability to decline, with its revenue holding steady. However, they disagree widely on these estimates.
CAT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $30.32 | +19% |
| Q3 2026 | $25.48 | +31% |
| Q2 2026 | $23.23 | +18% |
| Q1 2026 | $20.08 | -2% |
| Q4 2025 | $18.81 | -15% |
| Q3 2025 | $19.46 | -9.7% |
| Q2 2025 | $19.64 | -10% |
| Q1 2025 | $20.50 | -7.4% |
| Q4 2024 | $22.05 | +9.6% |
CAT has the edge over PSHG in the latest year-over-year earnings comparison.
PSHG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.61 | -33% |
| Q2 2026 | $0.91 | -42% |
| Q4 2025 | $1.28 | +15% |
| Q2 2025 | $1.56 | +6.8% |
| Q4 2024 | $1.11 | -42% |
| Q2 2024 | $1.46 | -75% |
| Q4 2023 | $1.91 | +$24.37 |
| Q4 2022 | -$22.46 | +$6.49 |
| Q4 2021 | -$28.95 | -284% |
PSHG's earnings per share have fallen from their peak: $0.91 over the past year, against $15.75 in late 2020.
CAT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.7B | +17% |
| Q2 2026 | $20.5B | +24% |
| Q1 2026 | $17.4B | +22% |
| Q4 2025 | $19.1B | +18% |
| Q3 2025 | $17.6B | +9.5% |
| Q2 2025 | $16.6B | -0.7% |
| Q1 2025 | $14.2B | -9.8% |
| Q4 2024 | $16.2B | -5% |
CAT's revenue has grown year over year for five quarters in a row: $20.7B last quarter, up 17% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +3.1 points |
| Q2 2026 | 21% | +3.6 points |
| Q1 2026 | 18% | -0.4 points |
| Q4 2025 | 14% | -4.1 points |
| Q3 2025 | 17% | -2.2 points |
| Q2 2025 | 17% | -3.6 points |
| Q1 2025 | 18% | -4.2 points |
| Q4 2024 | 18% | -0.3 points |
CAT's operating margin was 20% last quarter, up 3.1 points from the same quarter a year ago.
PSHG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $68.4M | +73% |
| Q4 2025 | $44.7M | +0.3% |
| Q2 2025 | $39.5M | -7.9% |
| Q4 2024 | $44.6M | -7.1% |
| Q2 2024 | $42.9M | -30% |
| Q4 2023 | $48M | -3.9% |
| Q2 2023 | $61M | +141% |
| Q4 2022 | $49.9M | +37% |
PSHG has the edge over CAT in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 47% | -2 points |
| Q4 2025 | 34% | -46 points |
| Q2 2025 | 93% | +32 points |
| Q4 2024 | 47% | -28 points |
| Q2 2024 | 49% | +38 points |
| Q4 2023 | 80% | +103 points |
| Q2 2023 | 61% | +90 points |
| Q4 2022 | 74% | +64 points |
PSHG has the edge over CAT on profitability, with a higher operating margin.
CAT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.7B | +19% |
| Q2 2026 | $3.8B | +47% |
| Q1 2026 | $1.1B | +97% |
| Q4 2025 | $2.7B | +0.1% |
| Q3 2025 | $3.1B | -1.5% |
| Q2 2025 | $2.6B | -4.2% |
| Q1 2025 | $579M | -63% |
| Q4 2024 | $2.7B | -22% |
CAT generated $11.3B in free cash flow over the past year, up 26% from the year before.
PSHG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2024 | $28M | +3% |
| Q2 2024 | $31.7M | -21% |
| Q4 2023 | $27.1M | -21% |
| Q2 2023 | $40.3M | +$44.7M |
| Q4 2022 | $34.5M | +$39.4M |
| Q2 2022 | -$4.4M | -$2.8M |
| Q4 2021 | -$4.9M | -137% |
| Q4 2020 | $13.2M | +$67.5M |
PSHG has burned cash in most quarters: $93M over the past year, up 42% from the year before.
CAT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -1.6M shares |
| 1 year | -2.1% | -9.9M shares |
| 3 years | -10% | -51.7M shares |
| 5 years | -16% | -86.7M shares |
| Available history | -19% | -107M shares |
CAT has the edge over PSHG on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.2B |
| Q2 2026 | $1.5B |
| Q1 2026 | $5B |
| Q4 2025 | $340M |
| Q3 2025 | $362M |
| Q2 2025 | $828M |
| Q1 2025 | $3.7B |
| Q4 2024 | $640M |
CAT spent $8.1B buying back its own shares over the past year, up 47% from the year before.
PSHG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +171K shares |
| 1 year | -0.3% | -119K shares |
PSHG has 39M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q2 2024 | — |
| Q4 2023 | $1.3M |
| Q2 2023 | $1.4M |
| Q4 2021 | — |
| Q2 2021 | — |
| Q4 2020 | $656,000 |
CAT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.5x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | 2.0x | Healthy |
| Q3 2025 | -0.6x | Net Cash |
| Q2 2025 | -0.4x | Net Cash |
| Q1 2025 | -0.3x | Net Cash |
| Q4 2024 | 1.6x | Healthy |
CAT has more cash than debt.
PSHG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2025 | -0.7x | Net Cash |
| Q4 2024 | -0.4x | Net Cash |
| Q2 2024 | -0.1x | Net Cash |
| Q4 2023 | -0.1x | Net Cash |
| Q2 2023 | 0.6x | Very low |
| Q4 2022 | 1.8x | Healthy |
| Q4 2020 | 3.6x | Elevated |
| Q4 2015 | 42.5x | High |
PSHG has more cash than debt.
CAT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.7 | Neutral |
| Stochastic | 6.7 | Oversold |
CAT's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
PSHG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 60.1 | Neutral |
| Stochastic | 65.2 | Neutral |
PSHG's weekly RSI is 60 (neutral) and its Stochastic is 65 (neutral).
CAT PE vs Industrials Sector
| Metric | CAT | Sector median | Relative |
|---|---|---|---|
| PE | 24x | 24x | 1.3% below |
| PE % | 69 | 58 | 11 pts above |
CAT is trading at 24x earnings, in line with the Industrials sector's median of 24x.
PSHG PE vs Industrials Sector
| Metric | PSHG | Sector median | Relative |
|---|---|---|---|
| PE | 2.2x | 24x | 91% below |
| PE % | 99 | 58 | 41 pts above |
PSHG has the edge over CAT on valuation relative to its sector.
CAT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $709.0 | 15% below |
| 20 week MA | $797.0 | 24% below |
| 50 week MA | $771.3 | 22% below |
| 100 week MA | $586.7 | 3.2% above |
| 200 week MA | $443.1 | 37% above |
CAT has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 37% above its 200-week average.
PSHG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.75 | 15% above |
| 20 week MA | $1.74 | 16% above |
| 50 week MA | $1.89 | 6.9% above |
| 100 week MA | $1.82 | 11% above |
| 200 week MA | $1.80 | 12% above |
PSHG has the edge over CAT on trend strength, trading above more of its moving averages.
CAT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $148.3 | $179.6 | +21% |
| 2021 | $179.6 | $206.2 | +15% |
| 2022 | $206.2 | $239.9 | +16% |
| 2023 | $239.9 | $295.7 | +23% |
| 2024 | $295.7 | $364.9 | +23% |
| 2025 | $364.9 | $583.0 | +60% |
| 2026 YTD | $583.0 | $605.3 | +3.8% |
CAT has the edge over PSHG on returns for 2026, with the stronger performance.
PSHG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $124.5 | $75.9 | -39% |
| 2021 | $75.9 | $67.7 | -11% |
| 2022 | $67.7 | $3.28 | -95% |
| 2023 | $3.28 | $2.27 | -31% |
| 2024 | $2.27 | $1.83 | -19% |
| 2025 | $1.83 | $2.31 | +26% |
| 2026 YTD | $2.31 | $2.02 | -13% |
PSHG has finished lower in five of the last six years. It's down 13% so far in 2026.